Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027

ELUTIA INC.

Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.
Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.
Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.
Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.